This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Shojaei, F. Articles by Ferrara, N. PubMed PubMed Citation Articles by Shojaei, F. Articles by Ferrara, N. Related Collections Tumor Biology Tumor Biology: Angiogenesis Cancer Immunology Cancer Immunology: Innate Immunity

Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells

Genentech, Inc., South San Francisco, California

Requests for reprints: Napoleone Ferrara, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225 2968; Fax: 650-225 4265; E-mail: nf{at}gene.com.

Key Words: angiogenesis • VEGF • tumor • stroma • CD11b+Gr1+ Cells

CD11b+Gr1+ cells, which include neutrophils, macrophages, and myeloid-derived suppressor cells, have been shown to contribute to tumor angiogenesis. Recently, we found that accumulation of CD11b+Gr1+ in tumors renders them refractory to angiogenic blockade by vascular endothelial growth factor (VEGF) antibodies. This effect was traced to a pathway of CD11b+Gr1+–mediated angiogenesis that is, at least in part, driven by the secreted protein Bv8, which is up-regulated by the important myeloid growth factor granulocyte colony-stimulating factor (G-CSF). Thus, G-CSF may promote tumor angiogenesis through a Bv8-dependent pathway that bypasses VEGF and renders tumors refractory to anti-VEGF therapy. [Cancer Res 2008;68(14):5501–4]

This article has been cited by other articles:

				G. C. Prendergast Myc and VEGF: Cancer Needs and Evasions Cancer Reviews Online Content, August 1, 2008; 2008(8): 15 - 15. [Full Text] [PDF]